title: [Pott's disease in a Colombian indigenous man].
abstract: Approximately 2 million people die each year from tuberculosis. One third of the world´s population is estimated to be infected with the tuberculosis bacillus, although only 5-10% will develop the disease in their lifetime. The disease progression risk depends on endogenous and exogenous factors. Indigenous communities are a high-risk group for infection and development of tuberculosis. In addition to factors such as geographical isolation, social and cultural neglect and malnutrition, susceptibility to genetic polymorphisms has been identified in them. Spinal tuberculosis is the most destructive form of the disease, which represents approximately half of all cases of skeletal tuberculosis. The case of an HIV negative, indigenous Colombian man is presented. His diagnosis was done based on clinical and image findings, and it was confirmed with the rapid molecular assay Genotype MTBDRplus® and IS6110 PCR.The culture in solid media was negative after 16 weeks. We briefly discuss the pathogenesis, diagnosis and treatment. Finally, we comment on some aspects of the situation of tuberculosis among indigenous Colombian communities.
authors: Dirección de Investigación, Fundación Universitaria Navarra, Neiva, Colombia.
authors: Leonardo F
authors: LF
authors: Jurado
authors: Laboratorio de Micobacterias, Grupo de Investigación MICOBAC-UN, Departamento de Microbiología, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C, Colombia.
authors: Martha I
authors: MI
authors: Murcia
authors: Unidad de Neurocirugía, Departamento de Cirugía, Facultad de Medicina, Universidad Nacional de Colombia.
authors: Jaime
authors: J
authors: Arias
authors: Laboratorio de Micobacterias, Grupo de Investigación MICOBAC-UN, Departamento de Microbiología, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C, Colombia.
authors: Liliana
authors: L
authors: Sánchez
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D003105:Colombia / Q000453:epidemiology; D003131:Combined Modality Therapy; D015299:Discitis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000601:surgery; D004198:Disease Susceptibility; D004322:Drainage; D024901:Drug Resistance, Multiple, Bacterial; D018023:HIV Seronegativity; D006801:Humans; D007199:Indians, South American; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification; D014057:Tomography, X-Ray Computed; D014376:Tuberculosis / Q000453:epidemiology; D014399:Tuberculosis, Spinal / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000453:epidemiology* / Q000601:surgery
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents